Hormone-refractory Prostate Cancer? Anti-androgen Withdrawal and Intermittent Hormone Therapy

By Sciarra Alessandro   Casale Paolo   Colella Dario   Chiro Costantino Di   Silverio Franco Di  

Scandinavian Journal of Urology and Nephrology, Vol. 33, Iss. 4, 1999-09 ,pp. : 211-216

Informa Healthcare

Access to resources Recommend Favorite

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer

By Schellhammer P.   Sharifi R.   Block N.   Soloway M.   Venner P.   Patterson A.L.   Sarosdy M.   Vogelzang N.   Jones J.   Kolvenbag G.  

Urology, Vol. 45, Iss. 5, 1995-05 ,pp. : 745-752

Elsevier

Access to resources Recommend Favorite

Chromogranin a in monitoring response and prognosis of hormone refractory prostate cancer

By Lapini A.   Meliani E.   Semi S.   Masieri L.   Farina U.   Corvino C.   Carini M.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 189-189

Elsevier

Access to resources Recommend Favorite

Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer

By Zagars G.K.   Pollack A.   von Eschenbach A.C.  

Urology, Vol. 58, Iss. 2, 2001-08 ,pp. : 233-239

Elsevier

Access to resources Recommend Favorite

Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed - a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

By Ornstein D.K.   Smith D.S.   Andriole G.L.  

Urology, Vol. 52, Iss. 6, 1998-12 ,pp. : 1094-1097

Elsevier

Access to resources Recommend Favorite